How Long Can You Stay on HRT? Rethinking Limits
SaveHormone therapy has no universal five-year limit. Guidelines now individualize how long you stay on it, based on symptoms, personal risk, and preference, with periodic review. For healthy women who start before 60 or within 10 years of menopause, continuing longer is reasonable when benefits still outweigh risks.
Last updated: July 2026
Where did the five-year rule come from?
The idea that hormone therapy must stop at five years grew out of the alarm following the 2002 Women's Health Initiative results 3Ref 3Manson JE, Aragaki AK, Rossouw JE, et al. (2017).Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the Women's Health Initiative randomized trials.Eighteen-year WHI follow-up finding no increase in all-cause mortality with either estrogen-alone or combined hormone therapy.. Early reporting emphasized elevated risks from combined therapy, and many clinicians responded with blanket time limits 4Ref 4Chlebowski RT, Anderson GL, Aragaki AK, et al. (2020).Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the Women's Health Initiative randomized clinical trials.Long-term WHI follow-up: combined estrogen-progestogen associated with increased breast cancer risk that grew with duration, while estrogen-alone was not.. Later analysis reframed those findings: the trial enrolled women who were older, on average 63, and often more than a decade past menopause, a group at higher baseline cardiovascular risk 3Ref 3Manson JE, Aragaki AK, Rossouw JE, et al. (2017).Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the Women's Health Initiative randomized trials.Eighteen-year WHI follow-up finding no increase in all-cause mortality with either estrogen-alone or combined hormone therapy.. The current guideline no longer supports a one-size-fits-all stopping point 1Ref 1The North American Menopause Society (Menopause Society) (2022).The 2022 Hormone Therapy Position Statement of The North American Menopause Society.No arbitrary duration limit; individualized duration with periodic review; continuation past 60 in appropriate candidates; longer therapy advised for premature or early menopause; route-related clot risk.. According to the North American Menopause Society, duration should be individualized rather than capped at an arbitrary number of years 1Ref 1The North American Menopause Society (Menopause Society) (2022).The 2022 Hormone Therapy Position Statement of The North American Menopause Society.No arbitrary duration limit; individualized duration with periodic review; continuation past 60 in appropriate candidates; longer therapy advised for premature or early menopause; route-related clot risk..
Is there a maximum time on HRT?
No official maximum duration applies to everyone. The North American Menopause Society states that hormone therapy can continue beyond age 60 or 65 in women who start early and remain good candidates, provided the reasons for use and the risk-benefit balance are reviewed regularly 1Ref 1The North American Menopause Society (Menopause Society) (2022).The 2022 Hormone Therapy Position Statement of The North American Menopause Society.No arbitrary duration limit; individualized duration with periodic review; continuation past 60 in appropriate candidates; longer therapy advised for premature or early menopause; route-related clot risk.. For younger women with premature or early menopause, therapy is generally advised at least until the usual age of natural menopause, a different situation from midlife symptom relief 1Ref 1The North American Menopause Society (Menopause Society) (2022).The 2022 Hormone Therapy Position Statement of The North American Menopause Society.No arbitrary duration limit; individualized duration with periodic review; continuation past 60 in appropriate candidates; longer therapy advised for premature or early menopause; route-related clot risk.. A Cochrane review of long-term hormone therapy found that absolute risks for most outcomes are small and depend on age, regimen, and duration 2Ref 2Marjoribanks J, Farquhar C, Roberts H, Lethaby A, Lee J (2017).Long-term hormone therapy for perimenopausal and postmenopausal women.Cochrane review of long-term hormone therapy showing small absolute risks that vary by age, regimen, and duration.. Ongoing use is a series of renewable decisions, not a single deadline.
How does risk change the longer you take HRT?
Some risks do shift with duration, which is why review matters. In long-term follow-up of the Women's Health Initiative, estrogen plus progestogen was linked to a modest rise in breast cancer risk that grew with longer use, while estrogen alone was not 4Ref 4Chlebowski RT, Anderson GL, Aragaki AK, et al. (2020).Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the Women's Health Initiative randomized clinical trials.Long-term WHI follow-up: combined estrogen-progestogen associated with increased breast cancer risk that grew with duration, while estrogen-alone was not.. The absolute increase is small for most people, and an 18-year follow-up found no rise in all-cause mortality with either regimen 3Ref 3Manson JE, Aragaki AK, Rossouw JE, et al. (2017).Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the Women's Health Initiative randomized trials.Eighteen-year WHI follow-up finding no increase in all-cause mortality with either estrogen-alone or combined hormone therapy.. Clot and stroke risks relate more to the route and age at use than to years on therapy, with transdermal estrogen carrying lower clot risk than tablets 1Ref 1The North American Menopause Society (Menopause Society) (2022).The 2022 Hormone Therapy Position Statement of The North American Menopause Society.No arbitrary duration limit; individualized duration with periodic review; continuation past 60 in appropriate candidates; longer therapy advised for premature or early menopause; route-related clot risk.. Weighing the benefits and risks of HRT over time is the heart of the duration question 1Ref 1The North American Menopause Society (Menopause Society) (2022).The 2022 Hormone Therapy Position Statement of The North American Menopause Society.No arbitrary duration limit; individualized duration with periodic review; continuation past 60 in appropriate candidates; longer therapy advised for premature or early menopause; route-related clot risk..
What guides the decision to continue or stop?
Whether to continue comes down to a handful of personal factors, not the calendar. Ongoing symptom severity is central: many women find hot flashes and night sweats return when they stop, and how long menopause symptoms last varies widely 1Ref 1The North American Menopause Society (Menopause Society) (2022).The 2022 Hormone Therapy Position Statement of The North American Menopause Society.No arbitrary duration limit; individualized duration with periodic review; continuation past 60 in appropriate candidates; longer therapy advised for premature or early menopause; route-related clot risk.. Bone protection matters too, since estrogen reduces fracture risk, and stopping removes that benefit 1Ref 1The North American Menopause Society (Menopause Society) (2022).The 2022 Hormone Therapy Position Statement of The North American Menopause Society.No arbitrary duration limit; individualized duration with periodic review; continuation past 60 in appropriate candidates; longer therapy advised for premature or early menopause; route-related clot risk.. According to the North American Menopause Society, there is no requirement to taper off by a set age if benefits still outweigh risks, though lower doses are often tried over time 1Ref 1The North American Menopause Society (Menopause Society) (2022).The 2022 Hormone Therapy Position Statement of The North American Menopause Society.No arbitrary duration limit; individualized duration with periodic review; continuation past 60 in appropriate candidates; longer therapy advised for premature or early menopause; route-related clot risk.. Local vaginal dryness treatment can continue indefinitely with minimal absorption even if systemic therapy stops 1Ref 1The North American Menopause Society (Menopause Society) (2022).The 2022 Hormone Therapy Position Statement of The North American Menopause Society.No arbitrary duration limit; individualized duration with periodic review; continuation past 60 in appropriate candidates; longer therapy advised for premature or early menopause; route-related clot risk..
When HRT duration questions need a clinician
A clinician helps turn the duration question into a periodic, informed check-in. Someone approaching a milestone birthday or a change in health benefits from revisiting whether hormone therapy still fits, rather than stopping by reflex 1Ref 1The North American Menopause Society (Menopause Society) (2022).The 2022 Hormone Therapy Position Statement of The North American Menopause Society.No arbitrary duration limit; individualized duration with periodic review; continuation past 60 in appropriate candidates; longer therapy advised for premature or early menopause; route-related clot risk.. A gynecologist or menopause-experienced clinician can weigh your symptoms, bone and heart health, and family history, then adjust the dose or route as circumstances change 1Ref 1The North American Menopause Society (Menopause Society) (2022).The 2022 Hormone Therapy Position Statement of The North American Menopause Society.No arbitrary duration limit; individualized duration with periodic review; continuation past 60 in appropriate candidates; longer therapy advised for premature or early menopause; route-related clot risk.. Because the evidence has shifted so much since 2002, an up-to-date conversation matters more than old rules of thumb 3Ref 3Manson JE, Aragaki AK, Rossouw JE, et al. (2017).Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the Women's Health Initiative randomized trials.Eighteen-year WHI follow-up finding no increase in all-cause mortality with either estrogen-alone or combined hormone therapy.. Gale can help you prepare for that conversation.
Common questions
Related
Menopause & midlife
Stopping HRT: Tapering, Timing, and ReboundMenopause & midlife
Who's a Good Candidate for HRT — and Who Isn'tMenopause & midlife
Starting HRT After 60: The Timing Question
Say it back
How would you explain this to someone you love?
Two or three sentences, just as you’d say it. Gale reflects back what you focused on — a mirror, not a quiz.
When to review staying on HRT
- —A new breast lump, or breast changes noticed during long-term therapy, is a reason to arrange a clinical examination.
- —Unscheduled or postmenopausal bleeding while on hormone therapy is a reason to seek clinician review.
- —A new diagnosis of a blood clot, stroke, heart disease, or breast cancer is a reason to reassess hormone therapy with your clinician.
- —Sudden breathlessness, chest pain, or a hot, swollen, painful calf can signal a blood clot and is a reason to seek urgent medical care.
This article is general health education, not medical advice. How long to continue hormone therapy is an individual decision to revisit periodically with a gynecologist or a menopause-experienced clinician.
References
- 1.The North American Menopause Society (Menopause Society) (2022). The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause. doi:10.1097/GME.0000000000002028 ✓No arbitrary duration limit; individualized duration with periodic review; continuation past 60 in appropriate candidates; longer therapy advised for premature or early menopause; route-related clot risk.
- 2.Marjoribanks J, Farquhar C, Roberts H, Lethaby A, Lee J (2017). Long-term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database of Systematic Reviews. doi:10.1002/14651858.CD004143.pub5 ✓Cochrane review of long-term hormone therapy showing small absolute risks that vary by age, regimen, and duration.
- 3.Manson JE, Aragaki AK, Rossouw JE, et al. (2017). Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the Women's Health Initiative randomized trials. JAMA. doi:10.1001/jama.2017.11217 ✓Eighteen-year WHI follow-up finding no increase in all-cause mortality with either estrogen-alone or combined hormone therapy.
- 4.Chlebowski RT, Anderson GL, Aragaki AK, et al. (2020). Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the Women's Health Initiative randomized clinical trials. JAMA. doi:10.1001/jama.2020.9482 ✓Long-term WHI follow-up: combined estrogen-progestogen associated with increased breast cancer risk that grew with duration, while estrogen-alone was not.
4 sources, numbered by first appearance. General health information, not medical advice. AI-assisted editorial content — every citation independently verified. Editorial policy